Akihiko Sekizawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8257947/publications.pdf Version: 2024-02-01

		109137	149479
115	3,714	35	56
papers	citations	h-index	g-index
117	117	117	2709
117	117	117	2798
all docs	docs citations	times ranked	citing authors

Ŧ	ARTICLE	IF	CHAILONS
1	Guidelines for obstetrical practice in <scp>J</scp> apan: <scp>J</scp> apan <scp>S</scp> ociety of <scp>O</scp> bstetrics and <scp>G</scp> ynecology (<scp>JSOG</scp>) and <scp>J</scp> apan <scp>A</scp> sociation of <scp>O</scp> bstetricians and <scp>G</scp> ynecologists (<scp>JAOG</scp>) 2014 edition. Journal of Obstetrics and Gynaecology Research, 2014, 40, 1469-1499.	0.6	307
2	Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet, The, 2000, 356, 1170.	6.3	238
3	Increased Cell-free Fetal DNA in Plasma of Two Women with Invasive Placenta. Clinical Chemistry, 2002, 48, 353-354.	1.5	122
4	Accuracy of Fetal Gender Determination by Analysis of DNA in Maternal Plasma. Clinical Chemistry, 2001, 47, 1856-1858.	1.5	120
5	Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. American Journal of Obstetrics and Gynecology, 2003, 188, 480-484.	0.7	116
6	Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. Prenatal Diagnosis, 2000, 20, 886-889.	1.1	98
7	p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecologic Oncology, 2003, 88, 318-325.	0.6	97
8	Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenatal Diagnosis, 2008, 28, 956-961.	1.1	87
9	Cell-free Fetal DNA Is Increased in Plasma of Women with Hyperemesis Gravidarum. Clinical Chemistry, 2001, 47, 2164-2165.	1.5	83
10	Prenatal diagnosis of the fetal RHD blood type using a single fetal nucleated erythrocyte from maternal blood. Obstetrics and Gynecology, 1996, 87, 501-505.	1.2	75
11	Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. American Journal of Obstetrics and Gynecology, 2019, 221, 650.e16.	0.7	73
12	Cell-free mRNA concentrations of CRH,PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenatal Diagnosis, 2007, 27, 772-777.	1.1	66
13	PP13 mRNA Expression in Trophoblasts From Preeclamptic Placentas. Reproductive Sciences, 2009, 16, 408-413.	1.1	63
14	Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenatal Diagnosis, 2004, 24, 83-86.	1.1	59
15	Nationwide demonstration project of nextâ€generation sequencing of cellâ€free DNA in maternal plasma in Japan: 1â€year experience. Prenatal Diagnosis, 2015, 35, 331-336.	1.1	59
16	Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. Journal of Human Genetics, 2016, 61, 647-652.	1.1	59
17	Detection of Cardiac Structural Abnormalities in Fetal Ultrasound Videos Using Deep Learning. Applied Sciences (Switzerland), 2021, 11, 371.	1.3	59
18	Total cell-free DNA(β-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. Prenatal Diagnosis, 2004, 24, 722-726.	1.1	57

Ακιμικό Sekizawa

#	Article	IF	CITATIONS
19	Cell-Free mRNA Concentrations of Plasminogen Activator Inhibitor-1 and Tissue-Type Plasminogen Activator Are Increased in the Plasma of Pregnant Women with Preeclampsia. Clinical Chemistry, 2007, 53, 399-404.	1.5	54
20	Within-Host Variations of Human Papillomavirus Reveal APOBEC Signature Mutagenesis in the Viral Genome. Journal of Virology, 2018, 92, .	1.5	52
21	Evaluation of bidirectional transfer of plasma DNA through placenta. Human Genetics, 2003, 113, 307-310.	1.8	51
22	K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 2004, 37, 188-92.	1.8	50
23	Relationship between Severity of Hyperemesis Gravidarum and Fetal DNA Concentration in Maternal Plasma. Clinical Chemistry, 2003, 49, 1667-1669.	1.5	48
24	Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. Prenatal Diagnosis, 2005, 25, 604-607.	1.1	48
25	Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. American Journal of Obstetrics and Gynecology, 2009, 200, 386.e1-386.e7.	0.7	48
26	Quantitative distribution of a panel of circulating mRNA in preeclampsiaversus controls. Prenatal Diagnosis, 2006, 26, 1115-1120.	1.1	47
27	Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. American Journal of Obstetrics and Gynecology, 2010, 203, 575.e1-575.e7.	0.7	45
28	Image Segmentation of the Ventricular Septum in Fetal Cardiac Ultrasound Videos Based on Deep Learning Using Time-Series Information. Biomolecules, 2020, 10, 1526.	1.8	45
29	The Role of p53 Mutation in the Carcinomas Arising from Endometriosis. International Journal of Gynecological Pathology, 2007, 26, 345-351.	0.9	43
30	Performance of a panel of maternal serum markers in predicting preeclampsia at 11–15 weeks' gestation. Prenatal Diagnosis, 2007, 27, 1005-1010.	1.1	43
31	Comparison of fetal cell recovery from maternal blood using a high density gradient for the initial separation step: 1.090 versus 1.119 g/ml. , 2000, 20, 281-286.		40
32	Cellular mRNA expressions of antiâ€oxidant factors in the blood of preeclamptic women. Prenatal Diagnosis, 2009, 29, 691-696.	1.1	40
33	Attitudes toward nonâ€invasive prenatal diagnosis among pregnant women and health professionals in Japan. Prenatal Diagnosis, 2012, 32, 674-679.	1.1	40
34	Current status of nonâ€invasive prenatal testing in Japan. Journal of Obstetrics and Gynaecology Research, 2017, 43, 1245-1255.	0.6	40
35	Female fetal cells in maternal blood: use of DNA polymorphisms to prove origin. Human Genetics, 2000, 107, 28-32.	1.8	38
36	Improvement of Fetal Cell Recovery from Maternal Blood: Suitable Density Gradient for FACS Separation. Fetal Diagnosis and Therapy, 1999, 14, 229-233.	0.6	37

#	Article	IF	CITATIONS
37	β-globin DNA in maternal plasma as a molecular marker of pre-eclampsia. Prenatal Diagnosis, 2004, 24, 697-700.	1.1	36
38	Placenta Increta: Postpartum Monitoring of Plasma Cell-free Fetal DNA. Clinical Chemistry, 2003, 49, 1540-1541.	1.5	34
39	Prenatal diagnosis of ornithine transcarbamylase deficiency by using a single nucleated erythrocyte from maternal blood. Human Genetics, 1998, 102, 611-615.	1.8	33
40	Placenta-Derived, Cellular Messenger RNA Expression in the Maternal Blood of Preeclamptic Women. Obstetrics and Gynecology, 2007, 110, 1130-1136.	1.2	33
41	Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. American Journal of Obstetrics and Gynecology, 2008, 198, 124.e1-124.e7.	0.7	32
42	Fetal cell recycling: Diagnosis of gender and RhD genotype in the same fetal cell retrieved from maternal blood. American Journal of Obstetrics and Gynecology, 1999, 181, 1237-1242.	0.7	31
43	Expression of Angiogenesis-Related Genes in the Cellular Component of the Blood of Preeclamptic Women. Reproductive Sciences, 2009, 16, 857-864.	1.1	31
44	Increased cell-free fetal DNA in plasma of two women with invasive placenta. Clinical Chemistry, 2002, 48, 353-4.	1.5	30
45	Proteinuria and Hypertension Are Independent Factors Affecting Fetal DNA Values: A Retrospective Analysis of Affected and Unaffected Patients. Clinical Chemistry, 2004, 50, 221-224.	1.5	29
46	Cell-free fetal DNA(SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenatal Diagnosis, 2004, 24, 293-297.	1.1	29
47	Recent advances in nonâ€invasive prenatal DNA diagnosis through analysis of maternal blood. Journal of Obstetrics and Gynaecology Research, 2007, 33, 747-764.	0.6	29
48	Model-Agnostic Method for Thoracic Wall Segmentation in Fetal Ultrasound Videos. Biomolecules, 2020, 10, 1691.	1.8	28
49	PP13 mRNA expression in the cellular component of maternal blood as a marker for preeclampsia. Prenatal Diagnosis, 2009, 29, 1231-1236.	1.1	27
50	Classification of factors involved in nonreportable results of noninvasive prenatal testing (NIPT) and prediction of success rate of second NIPT. Prenatal Diagnosis, 2019, 39, 100-106.	1.1	27
51	Testing normality of fetal DNA concentration in maternal plasma at 10-12 completed weeks' gestation: a preliminary approach to a new marker for genetic screening. Prenatal Diagnosis, 2002, 22, 148-152.	1.1	26
52	Enrichment of NRBC in maternal blood: a more feasible method for noninvasive prenatal diagnosis. Prenatal Diagnosis, 2006, 26, 545-547.	1.1	25
53	Lower Maternal PLAC1 mRNA in Pregnancies Complicated with Vaginal Bleeding (Threatened Abortion) Tj ETQq	1 1 0.7843 1.5	314.rgBT /Ove
54	Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening. Prenatal Diagnosis, 2009, 29, 1038-1044.	1.1	24

Ακιμικό Sekizawa

#	Article	lF	CITATIONS
55	Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 2004, 37, 97-100.	1.8	23
56	Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. Journal of Clinical Medicine, 2019, 8, 856.	1.0	23
57	Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 224, 165-169.	0.5	22
58	The use of balloons for uterine cervical ripening is associated with an increased risk of umbilical cord prolapse: population based questionnaire survey in Japan. BMC Pregnancy and Childbirth, 2015, 15, 4.	0.9	21
59	Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration. Scientific Reports, 2018, 8, 11205.	1.6	21
60	Shadow Estimation for Ultrasound Images Using Auto-Encoding Structures and Synthetic Shadows. Applied Sciences (Switzerland), 2021, 11, 1127.	1.3	21
61	Medical Professional Enhancement Using Explainable Artificial Intelligence in Fetal Cardiac Ultrasound Screening. Biomedicines, 2022, 10, 551.	1.4	21
62	Disappearance of Steroid Hormone Dependency During Malignant Transformation of Ovarian Clear Cell Cancer. International Journal of Gynecological Pathology, 2005, 24, 369-376.	0.9	20
63	Retrospective details of false-positive and false-negative results in non-invasive prenatal testing for fetal trisomies 21, 18 and 13. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 75-81.	0.5	20
64	3.BETAHydroxysteroid Dehydrogenase Activity in Human Osteoblast-Like Cells Endocrine Journal, 1997, 44, 847-853.	0.7	19
65	A survey on awareness of genetic counseling for non-invasive prenatal testing: the first year experience in Japan. Journal of Human Genetics, 2016, 61, 995-1001.	1.1	19
66	Fate of Fetal Nucleated Erythrocytes Circulating in Maternal Blood: Apoptosis Is Induced by Maternal Oxygen Concentration. Clinical Chemistry, 2002, 48, 1618-1620.	1.5	18
67	Development of noninvasive fetal DNA diagnosis from nucleated erythrocytes circulating in maternal blood. Prenatal Diagnosis, 2007, 27, 846-848.	1.1	18
68	Rapid Clearance of mRNA for PLAC1 Gene in Maternal Blood after Delivery. Fetal Diagnosis and Therapy, 2005, 20, 27-30.	0.6	15
69	Clinical Potential for Noninvasive Prenatal Diagnosis Through Detection of Fetal Cells in Maternal Blood. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 10-20.	0.5	15
70	Physiological Changes in the Pattern of Placental Gene Expression Early in the First Trimester. Reproductive Sciences, 2013, 20, 710-714.	1.1	15
71	Chromosome abnormalities diagnosed in utero: a Japanese study of 28 983 amniotic fluid specimens collected before 22 weeks gestations. Journal of Human Genetics, 2015, 60, 133-137.	1.1	15
72	Factors affecting parental decisions to terminate pregnancy in the presence of chromosome abnormalities: a Japanese multicenter study. Prenatal Diagnosis, 2016, 36, 1121-1126.	1.1	14

#	Article	IF	CITATIONS
73	Obstetric risk factors for umbilical cord prolapse: a nationwide population-based study in Japan. Archives of Gynecology and Obstetrics, 2016, 294, 467-472.	0.8	14
74	Clinical risk factors for poor neonatal outcomes in umbilical cord prolapse. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1652-1656.	0.7	14
75	Maternal Smoking and Placental Expression of a Panel of Genes Related to Angiogenesis and Oxidative Stress in Early Pregnancy. Fetal Diagnosis and Therapy, 2014, 35, 289-295.	0.6	13
76	Female fetal cells in maternal blood: use of DNA polymorphisms to prove origin. Human Genetics, 2000, 107, 28-32.	1.8	12
77	Circulating mRNA for the PLAC1 Gene as a Second Trimester Marker (14-18 Weeks' Gestation) in the Screening for Late Preeclampsia. Fetal Diagnosis and Therapy, 2014, 36, 196-201.	0.6	11
78	Whole-Genome Analysis of Human Papillomavirus Type 16 Prevalent in Japanese Women with or without Cervical Lesions. Viruses, 2019, 11, 350.	1.5	10
79	Higher circulating mRNA levels of placental specific genes in a patient with placenta accreta. Prenatal Diagnosis, 2011, 31, 827-829.	1.1	8
80	Tadalafil treatment for preeclampsia (medication in preeclampsia; MIE): a multicenter phase II clinical trial. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3709-3715.	0.7	8
81	Accuracy of the FMF Bayes theorem-based model for predicting preeclampsia at 11–13 weeks of gestation in a Japanese population. Hypertension Research, 2021, 44, 685-691.	1.5	8
82	Detection and Quantification of Fetal DNA in Maternal Plasma by Using LightCycler Technology. Methods in Molecular Biology, 2008, 444, 231-238.	0.4	8
83	Current Status of the Screening of Chlamydia trachomatis Infection Among Japanese Pregnant Women. Journal of Clinical Medicine Research, 2015, 7, 582-584.	0.6	8
84	Examination of clinical factors affecting intrauterine microbiota. Reproduction and Fertility, 2021, 2, 1-6.	0.6	7
85	Cell-Free Fetal DNA in Plasma of Pregnant Women: Clinical Potential and Origin. Taiwanese Journal of Obstetrics and Gynecology, 2005, 44, 116-122.	0.5	6
86	TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. BMJ Open, 2018, 8, e020948.	0.8	6
87	The routine use of prophylactic Bakri balloon tamponade contributes to blood loss control in major placenta previa. International Journal of Gynecology and Obstetrics, 2021, 154, 508-514.	1.0	6
88	Maternal Death Related to Sudden Unexpected Death in Epilepsy: A Nationwide Survey in Japan. Brain Sciences, 2021, 11, 995.	1.1	6
89	Fate of fetal nucleated erythrocytes circulating in maternal blood: apoptosis is induced by maternal oxygen concentration. Clinical Chemistry, 2002, 48, 1618-20.	1.5	6
90	A study of monoamine oxidase activity in fetal membranes. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 423-427.	1.3	5

#	Article	IF	CITATIONS
91	Next-Generation Sequencing Reveals Downregulation of the Wnt Signaling Pathway in Human Dysmature Cumulus Cells as a Hallmark for Evaluating Oocyte Quality. Reproductive Medicine, 2020, 1, 205-215.	0.3	5
92	Nationwide survey for current clinical status of amniocentesis and maternal serum marker test in Japan. Journal of Human Genetics, 2016, 61, 879-884.	1.1	4
93	Postpartum questionnaire survey of women who tested negative in a non-invasive prenatal testing: examining negative emotions towards the test. Journal of Human Genetics, 2021, 66, 579-584.	1.1	4
94	Successful monozygotic triplet pregnancy after a single blastocyst transfer following in vitro maturation of oocytes from a woman with polycystic ovary syndrome: a case report. BMC Pregnancy and Childbirth, 2020, 20, 57.	0.9	4
95	How do the trends in the prenatal diagnosis of aneuploidy change after a non-invasive prenatal test becomes available? A Japanese single center study. Journal of Medical Ultrasonics (2001), 2015, 42, 195-198.	0.6	3
96	Tadalafil treatment for fetuses with early-onset growth restriction: a protocol for a multicentre, randomised, placebo-controlled, double-blind phase II trial (TADAFER IIb). BMJ Open, 2022, 12, e054925.	0.8	3
97	Effects of Chemotherapy on Fertility Preservation in Patients with Tumors of the Hematopoietic and Lymphoid Tissues. Reproductive Medicine, 2022, 3, 141-149.	0.3	3
98	A Study of γâ€Aminobutyric Acid (GABA) in Amniotic Fluid. Journal of Obstetrics and Gynaecology Research, 1997, 23, 471-477.	0.6	2
99	Declined use of cervical ripening balloon did not reduce the incidence of umbilical cord prolapse in Japan. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1349-1354.	0.6	2
100	Infective endocarditis due to <scp> <i>Streptococcus agalactiae</i> </scp> in the puerperal period. Journal of Obstetrics and Gynaecology Research, 2021, 47, 2238-2241.	0.6	2
101	Evaluation of the clinical performance of noninvasive prenatal testing at a Japanese laboratory. Journal of Obstetrics and Gynaecology Research, 2021, 47, 3437-3446.	0.6	2
102	Evaluation of Second-generation HIFU Systems: Less-invasive Fetal Therapy for TRAP Sequence. The Showa University Journal of Medical Sciences, 2017, 29, 241-251.	0.1	2
103	Distribution of PAPP-A and total hCG between 11 and 13 weeks of gestation in Japanese pregnant women. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 2017-2022.	0.7	1
104	Successful Pregnancy in a Case of Behçet's Disease after Treatment with Prednisolone. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-5.	0.2	1
105	Fibrin Adhesive Spray Occlusion using a Laparoscope for Intractable Chylous Ascites: Case Report. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2014, 30, 188-192.	0.0	1
106	Prevalence of common aneuploidy in twin pregnancies. Journal of Human Genetics, 2022, 67, 261-265.	1.1	1
107	Predictive ability of serum advanced glycation end products at 11 to 13 weeks of gestation for early-onset preeclampsia. AJOG Global Reports, 2022, 2, 100052.	0.4	1
108	Assessment of the value of measuring soluble fms-like tyrosine kinase-1 and placental growth factor levels following administration of tadalafil to treat fetal growth restriction. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 9131-9135.	0.7	1

#	Article	IF	CITATIONS
109	Reference values of Focused Assessment with Sonography for Obstetrics (FASO) in low risk population. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 29, 1-17.	0.7	0
110	Three-Dimensional Peripheral Bloodstream Model of the Uterus for Laparoscopic Radical Hysterectomy. Journal of Minimally Invasive Gynecology, 2020, 27, 1196-1202.	0.3	0
111	Relationship between Malignant Transformation of Endometriosis and Genetic Alterations of K-ras and Microsatellite Instability. The Showa University Journal of Medical Sciences, 2004, 16, 47-54.	0.1	0
112	Fragmentation of Fetal DNA in Maternal Plasma and Urine. The Showa University Journal of Medical Sciences, 2005, 17, 81-87.	0.1	0
113	Quantitative RT-PCR Gene Expression Analysis of a Laser Microdissected Placenta: An Approach to Study Preeclampsia. Methods in Molecular Biology, 2011, 755, 477-489.	0.4	Ο
114	Prenatal Identification of Confined Placental Mosaicism in Pregnant Women with Fetal Growth Restriction. Reproductive Sciences, 2022, 29, 896-903.	1.1	0
115	Antimicrobial Resistance for <i>Chlamydia Trachomatis</i> Genital Infection during Pregnancy in Japan. Infection and Chemotherapy, 2022, 54, 173.	1.0	0